While labs overwhelmingly welcomed the ruling, it could make it more difficult for firms that want FDA's imprimatur for LDTs ...

The investment bank said that the company's recent organic growth is sustainable and noted consumer momentum and traction with advanced tests.

Last week, readers were most interested in a story about a report a possible sale of Qiagen, which sent its stock soaring.

The agreement complements Diasorin's US commercial organization and recently expanded sales force dedicated to the Liaison NES system.

The approach uses an iteration of the SHERLOCK technology exclusively licensed to OraSure Technologies' subsidiary, Sherlock Biosciences.

Medicare lab spending totaled $8.4 billion in 2024, up 5 percent year over year, with $3.6 billion of that spent on genetic testing, an increase of 20 percent over 2023.

The test can be used to detect HDV infection, a particularly dangerous coinfection that can occur with hepatitis B virus.

A special shareholder meeting is scheduled for next week to vote on the agreement to be acquired by Blackstone and TPG.

The stock split will reduce the company's outstanding common stock from approximately 2.8 million shares to about 709,000 shares.

The patent court found that two of Guardant's patents were likely invalid and that Guardant did not adequately demonstrate that Sophia infringed a third patent.

The test detects Borrelia bacteria directly from skin interstitial fluid samples from people with signs of tick bites or erythema migrans.

The company is the first commercial lab in the US to agree to implement the system, which it will begin using in the first quarter of the year.